Treatment of canine atopic dermatitis
AssigneeBenchmark Animal Health Limited
InventorKaspars TARS
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.
Claims15
A composition for use in a method of preventing or treating canine atopic dermatitis (CAD) of a canidae, preferably of a domestic dog, wherein an effective amount of said composition is administered to said canidae, preferably to said domestic dog, and wherein said composition comprises
- (a) a core particle with at least one first attachment site;
- and
- (b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with SEQ ID NO:22;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
The composition for use of any one of the preceding claims, wherein said core particle is a virus-like particle (VLP), preferably a recombinant VLP.
The composition for use of any one of the preceding claims, wherein said at least one cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from:
- (a) SEQ ID NO:18;
- (b) SEQ ID NO:21;
- (c) SEQ ID NO:22;
- or
- (d) SEQ ID NO:26.
The composition for use of any one of the preceding claims, wherein said administration of said composition reduces at least one CAD parameter or symptom as compared to said at least one CAD parameter or symptom before said administration, and wherein preferably said at least one CAD parameter or symptom is the level or severity grade of skin lesions or itching, and wherein further preferably said reduction of said level or severity grade of skin lesions is determined by a symptom and lesion scoring test.
A composition comprising
- (a) a virus-like particle (VLP) with at least one first attachment site;
- (b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with SEQ ID NO:22, and again further preferably said antigen comprises, or preferably consists of a protein with the amino sequence of SEQ ID NO:22;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
The composition of claim 13 or 14, wherein said VLP is a modified VLP of cucumber mosaic virus (CMV), wherein said modified CMV polypeptide comprises, preferably consists of, an amino acid sequence of SEQ ID NO:6 or SEQ ID NO:7.
Dependencies are inferred from the claim text.